Aranesp
Links shared publicly online about this topic
FDA: New Warning for Procrit, Epogen, Aranesp
webmd.com — “New data show that the way Procrit, Epogen, and Aranesp are used in patients with chronic kidney disease puts them at risk of heart attacks, stroke, and death. More conservative dosing is needed.” View full resource at webmd.com
Most Recently Shared on June 24, 2011 at 10:02 pm By:
FDA: New Warning for Procrit, Epogen, Aranesp: New data show that the way Procrit, Epogen, and Aranesp are used ... http://bit.ly/isAvpZ
Kidney Patients Not On Dialysis, FDA Advisers Recommend Continuation Of Aranesp (Darbepoetin Alfa)
medicalnewstoday.com — “An FDA Advisory Committee has recommended the continued use of Aranesp (Darbepoetin alfa), a synthetic form of erythropoietin used to treat anemia in patients with mild to moderate chronic (long-t” View full resource at medicalnewstoday.com
Most Recently Shared on October 19, 2010 at 1:08 am By:
Kidney Patients Not On Dialysis, FDA Advisers Recommend Continuation Of Aranesp (Darbepoetin Alfa) An FDA Advisory Comm.. http://dld.bz/2kd8
Heart Risks Rise for Kidney Patients on Higher Doses of Amgen's Aranesp - Bloomberg
bloomberg.com — “Diabetic patients with chronic kidney disease are more likely to suffer heart complications or die if they need higher doses of Amgen Inc. 's Aranesp to reach current treatment goals, researchers said.” View full resource at bloomberg.com
Most Recently Shared on September 16, 2010 at 1:32 am By:
Heart Risks Rise for Kidney Patients on Higher Doses of Amgen's Aranesp: Diabetic patients with chronic kidney dis... http://bit.ly/d2rkbk
Heart Risks Rise for Kidney Patients on Higher Doses of Amgen's Aranesp - Bloomberg
bloomberg.com — “Diabetic patients with chronic kidney disease are more likely to suffer heart complications or die if they need higher doses of Amgen Inc. 's Aranesp to reach current treatment goals, researchers said.” View full resource at bloomberg.com
Most Recently Shared on September 16, 2010 at 9:56 am By:
The Kidney Group Physician Group and Nephrology
Heart Risks Rise for Kidney Patients on Higher Doses of Amgen's Aranesphttp://bit.ly/bEsq28
Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp
fda.gov — “The FDA is requiring all drugs called Erythropoiesis-Stimulating Agents (ESAs) to be prescribed and used under a risk management program, known as a risk evaluation and mitigation strategy (REMS), to ensure the safe use of these drugs.” View full resource at fda.gov
Most Recently Shared on February 16, 2010 at 4:27 pm By:
eyeonfda Health Lawyer and Pharma
RT @FDA_Drug_Info: Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp: http://bit.ly/9hCNtM
ESC | Congresses | ESC Congress 2010 | TREAT: Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin) Therapy
escardio.org — “Congress reports 2010 - TREAT: Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin) Therapyby McMurray, John” View full resource at escardio.org
Most Recently Shared on September 2, 2010 at 12:32 am By:
Symposier Cardiology Cardiology and Health Business
TREAT: Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin) Therapy. http://bit.ly/dbpJ9p #ESC10
FDA: New Warning for Procrit, Epogen, Aranesp - Medications: Prescription Drugs and Over the Counter Drugs on MedicineNet.com
medicinenet.com — “Drug information on prescription and over the counter medications includes drug interactions, uses, side effects, and drug dosing.” View full resource at medicinenet.com
Most Recently Shared on June 28, 2011 at 8:24 am By:
RT @health_tweets FDA: New Warning for Procrit, Epogen, Aranesp - MedicineNet.com http://t.co/2MZ82i7
FDA Advisors Go Easy on Aranesp (darbepoetin alfa) « CardioBrief
cardiobrief.org — “FDA Advisors Go Easy on Aranesp (darbepoetin alfa) « CardioBrief” View full resource at cardiobrief.org
Most Recently Shared on October 18, 2010 at 10:59 pm By:
RenalFellowNetwork Health Site and Nephrology
RT @cardiobrief: FDA Advisors Go Easy on Aranesp (darbepoetin alfa): http://wp.me/ppMHd-1LU #fb
Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL
news-medical.net — “Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.” View full resource at news-medical.net
Most Recently Shared on August 26, 2009 at 1:59 pm By:
Stroke News: Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobi.. http://twurl.nl/zpvhnu
Study finds stroke risk from anemia drug Aranesp - USATODAY.com
rssfeeds.usatoday.com — “A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick enough to need dialysis.” View full resource at rssfeeds.usatoday.com
Most Recently Shared on October 31, 2009 at 12:58 am By:
Study finds stroke risk from anemia drug Aranesp http://bit.ly/4lHXhS
States Join Suit Alleging Amgen Offered Illegal Kickback To Doctors For Aranesp — The Cancer Letter
cancerletter.com — “From The Cancer Letter, Nov. 6, 2009:” View full resource at cancerletter.com
Most Recently Shared on November 6, 2009 at 8:56 pm By:
States join suit alleging Amgen kickbacks to docs for #Aranesp http://bit.ly/37v32N
RT @HEALTH_NOTES: - FDA announces 10/18 Cardiovascular & Renal Drugs AC mtg re TREAT ARANESP study - http://j.mp/aXYTrJ $AMGN $JNJ $DVA
ofr.gov — “RT @HEALTH_NOTES: - FDA announces 10/18 Cardiovascular & Renal Drugs AC mtg re TREAT ARANESP study - http://j.mp/aXYTrJ $AMGN $JNJ $DVA” View full resource at ofr.gov
Most Recently Shared on September 20, 2010 at 1:24 pm By:
eyeonfda Health Lawyer and Pharma
RT @HEALTH_NOTES: - FDA announces 10/18 Cardiovascular & Renal Drugs AC mtg re TREAT ARANESP study - http://j.mp/aXYTrJ $AMGN $JNJ $DVA
Aranesp Suit: What Did Amgen CEO Sharer Know (and Did He Read It in His Company's PowerPoint Slides)? | BNET Pharma Blog | BNET
industry.bnet.com — “Amgen executives detailed their alleged Aranesp “overfill” kickback scheme in a set of PowerPoint slides and Excel spreadsheets, according” View full resource at industry.bnet.com
Most Recently Shared on November 2, 2009 at 4:26 pm By:
Jim Edwards Health Communicator
Aranesp Suit: What Did Amgen CEO Sharer Know (and Did He Read It in His Company's PowerPoint Slides)?: Amgen executiv... http://bit.ly/5vS1h
Amgen Announces Top-Line Results Of Trial To Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) In CKD Patients With Type-2 Diabetes
medicalnewstoday.com — “Amgen (nasdaq: amgn) announced that in a large, randomized, double-blind, placebo-controlled, phase 3 study of patients with chronic kidney disease (ckd) (not requiring dialysis), anemia and type” View full resource at medicalnewstoday.com
Most Recently Shared on August 26, 2009 at 12:44 pm By:
Amgen Announces Top-Line Results Of Trial To Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) In CKD.. http://bit.ly/8yOKl
TREAT: Darbepoetin alfa fails in anemic diabetics with CKD
theheart.org — “No differences were seen between groups, except in strokes, which were twice as high in the active-treatment group. Anticipated improvements in fatigue scores were modest and not clinically meaningful, investigators say.” View full resource at theheart.org
Most Recently Shared on October 31, 2009 at 1:04 am By:
heartwire: No TREAT: Darbepoetin alfa fails to reduce CV or renal events in anemic diabetics with CKD http://bit.ly/2vsyPY
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
WebMD_News
The leading source for trustworthy and timely health news and information.
-
medical_tweets
-
Heart & Blood OW
Organizing heart and blood resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement
